Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Liposome Res ; 28(1): 5-13, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27733083

RESUMO

Keloids were characterized by excessive growth of fibrous tissues, and shared several pathological characteristics with cancer. They did put physical and emotional stress on patients in that keloids could badly change appearance of patients. N-(4-hydroxyphenyl) retinamide (4HPR) showed cytotoxic activity on a wide variety of invasive-growth cells. Our work was aim to prepare N-(4-hydroxyphenyl) retinamide-loaded lipid microbubbles (4HPR-LM) combined with ultrasound for anti-keloid therapy. 4HPR-loaded liposomes (4HPR-L) were first prepared by film evaporation method, and then 4HPR-LM were manufactured by mixing 4HPR-L and perfluoropentane (PFP) with ultrasonic cavitation method. The mean particle size and entrapment efficiency 4HPR-LM were 113 nm and 95%, respectively. The anti-keloids activity of 4HPR-LM was assessed with BALB/c nude mice bearing subcutaneous xenograft keloids model. 4HPR-LM, combined with ultrasound, could significantly induce apoptosis of keloid fibroblasts in vitro and inhibited growth of keloids in vivo. Thus, 4HPR-LM could be considered as a promising agent for anti-keloids therapy.


Assuntos
Fenretinida/farmacologia , Queloide/terapia , Lipídeos/química , Lipossomos , Nanopartículas , Ondas Ultrassônicas , Animais , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Fenretinida/química , Fibroblastos/citologia , Fibroblastos/efeitos dos fármacos , Humanos , Camundongos Endogâmicos BALB C , Camundongos Nus , Tamanho da Partícula , Propriedades de Superfície
2.
Acta Pharmacol Sin ; 34(11): 1457-66, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24056707

RESUMO

AIM: To investigate the roles of the calcineurin/nuclear factor of activated T cells (NFAT) pathway in regulation of wear particles-induced cytokine release and osteoclastogenesis from mouse bone marrow macrophages in vitro. METHODS: Osteoclasts were induced from mouse bone marrow macrophages (BMMs) in the presence of 100 ng/mL receptor activator of NF-κB ligand (RANKL). Acridine orange staining and MTT assay were used to detect the cell viability. Osteoclastogenesis was determined using TRAP staining and RT-PCR. Bone pit resorption assay was used to examine osteoclast phenotype. The expression and cellular localization of NFATc1 were examined using RT-PCR and immunofluorescent staining. The production of TNFα was analyzed with ELISA. RESULTS: Titanium (Ti) or polymethylmethacrylate (PMMA) particles (0.1 mg/mL) did not significantly change the viability of BMMs, but twice increased the differentiation of BMMs into mature osteoclasts, and markedly increased TNF-α production. The TNF-α level in the PMMA group was significantly higher than in the Ti group (96 h). The expression of NFATc1 was found in BMMs in the presence of the wear particles and RANKL. In bone pit resorption assay, the wear particles significantly increased the resorption area and total number of resorption pits in BMMs-seeded ivory slices. Addition of 11R-VIVIT peptide (a specific inhibitor of calcineurin-mediated NFAT activation, 2.0 µmol/L) did not significantly affect the viability of BMMs, but abolished almost all the wear particle-induced alterations in BMMs. Furthermore, VIVIT reduced TNF-α production much more efficiently in the PMMA group than in the Ti group (96 h). CONCLUSION: Calcineurin/NFAT pathway mediates wear particles-induced TNF-α release and osteoclastogenesis from BMMs. Blockade of this signaling pathway with VIVIT may provide a promising therapeutic modality for the treatment of periprosthetic osteolysis.


Assuntos
Calcineurina/metabolismo , Fatores de Transcrição NFATC/metabolismo , Oligopeptídeos/farmacologia , Osteoclastos/metabolismo , Animais , Células da Medula Óssea/citologia , Células da Medula Óssea/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ensaio de Imunoadsorção Enzimática , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Fatores de Transcrição NFATC/genética , Osteoclastos/efeitos dos fármacos , Polimetil Metacrilato/farmacologia , Ligante RANK/administração & dosagem , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais/efeitos dos fármacos , Titânio/farmacologia , Fator de Necrose Tumoral alfa/metabolismo
3.
Colloids Surf B Biointerfaces ; 203: 111723, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33839474

RESUMO

Although the biomedical sciences have achieved tremendous success in developing novel approaches to managing prostate cancer, this disease remains one of the major health concerns among men worldwide. Liposomal formulations of single drugs have shown promising results in cancer treatment; however, the use of multi drugs has shown a better therapeutic index than individual drugs. The identification of cancer-specific receptors has added value to design targeted drug delivering nanocarriers. We have developed genistein and plumbagin co-encapsulating liposomes (∼120 nm) with PSMA specific antibodies to target prostate cancer cells selectively in this work. These liposomes showed >90 % decrease in PSMA expressing prostate cancer cell proliferation without any appreciable toxicity to healthy cells and human red blood cells. Release of plumbagin and genistein was found to decrease the expression of PI3/AKT3 signaling proteins and Glut-1 receptors (inhibited glucose uptake and metabolism), respectively. The decrease in migration potential of cells and induced apoptosis established the observed anti-proliferative effect in prostate cancer cell lines. The discussed strategy of developing novel, non-toxic, and PSMA specific antibody conjugated liposomes carrying genistein and plumbagin drugs may also be used for encapsulating other drugs and inhibit the growth of different types of cancers.


Assuntos
Glutamato Carboxipeptidase II , Neoplasias da Próstata , Apoptose , Linhagem Celular Tumoral , Genisteína/farmacologia , Humanos , Lipossomos , Masculino , Naftoquinonas , Neoplasias da Próstata/tratamento farmacológico
4.
J Biomed Mater Res B Appl Biomater ; 101(6): 998-1005, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23529958

RESUMO

To improve the treatment of helminthiasis, filariasis, and colorectal cancer, albendazole-associated chitosan nanoparticles (ABZ-CS-NPs) were prepared using the emulsion crosslinking volatile technique with contained sodium tripolyphosphate as the crosslinking agent and Poloxamer 188 as the auxiliary solvent. The structural characteristics of the NPs were determined using X-ray diffraction to analyze the interaction between CS and the drug. The NPs were then evaluated in terms of their physicochemical characteristics, drug release behavior, in vivo pharmacokinetic parameters, and biodistribution in animal studies. ABZ-loaded NPs with a uniformly spherical particle sizes (157.8 ± 2.82 nm) showed efficient drug loading, encapsulated efficiency, and high physical stability. The drug release from ABZ-CS-NPs was extended over several periods. Kinetic models were then fitted to determine the release mechanisms. ABZ and its metabolite albendazole sulfoxide (ABZSX) were analyzed in rats with mebendazole as the internal standard using reversed-phase high-performance liquid chromatography. Compared with the ABZ suspension groups, the relative bioavailability values of ABZ and ABZSX were 146.05 and 222.15%, respectively. In addition, the plasma concentration versus time curve is consistent with that of the two compartment models in the plasma concentration versus time curve. The results indicate that the ABZ-loaded NPs are promising novel ABZ candidates for passive diffusion in the treatment of hydatid cysts in the liver via oral administration.


Assuntos
Albendazol/administração & dosagem , Anti-Helmínticos/administração & dosagem , Quitosana/química , Sistemas de Liberação de Medicamentos , Nanopartículas/química , Administração Oral , Albendazol/farmacocinética , Animais , Anti-Helmínticos/farmacocinética , Materiais Biocompatíveis/administração & dosagem , Materiais Biocompatíveis/química , Disponibilidade Biológica , Quitosana/administração & dosagem , Equinococose Hepática/tratamento farmacológico , Equinococose Hepática/metabolismo , Feminino , Absorção Intestinal , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Teste de Materiais , Camundongos , Camundongos Nus , Nanopartículas/administração & dosagem , Nanopartículas/ultraestrutura , Tamanho da Partícula , Ratos , Ratos Sprague-Dawley
5.
J Fluoresc ; 17(1): 81-7, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17143727

RESUMO

A highly sensitive and selective fluorogenic probe for fluoride ion, fluorescein di-tert-butyldimethylsilyl ether (FTBS), was designed and synthesized. FTBS was a colorless, non-fluorescent compound and was synthesized via the one-step reaction of fluorescein with tert-butyldimethylsilyl chloride. Upon incubation with fluoride ion in DMF-water solution (7 : 3, V/V), the Si-O bond of FTBS was cleaved, causing a large increase in fluorescence intensity and thereby allowing a selective detection of fluoride ion. The fluorescence increase is linearly with fluoride concentration in the range 0.1-2.0 mumol L(-1) with a detection limit of 0.041 mumol L(-1) (3sigma). The excellent selective signaling behavior of the proposed probe was found to originate from the high affinity of silicon toward fluoride ion. The method has been successfully applied to the fluoride determination in multi-trace elements injection and toothpaste samples, and the results are agreed well with those obtained by the fluoride-ion selective electrode method.


Assuntos
Fluoresceína/química , Corantes Fluorescentes/química , Fluoretos/química , Compostos de Organossilício/química , Estrutura Molecular , Compostos de Organossilício/síntese química , Sensibilidade e Especificidade , Espectrometria de Fluorescência , Cremes Dentais/química , Água/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA